Disease · MONDO_0005008
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Fruquintinib + BSC Group vs Placebo + BSC Group: Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed | 116 of 461 | 63 of 230 | 691 | NCT04322539 | Trial comparisons |
| Fruquintinib + BSC Group vs Placebo + BSC Group: deaths from any cause | 411 of 461 | 203 of 230 | 691 | NCT04322539 | Trial comparisons |
| Fruquintinib + BSC Group vs Placebo + BSC Group: serious adverse events | 173 of 456 | 88 of 230 | 686 | NCT04322539 | Trial comparisons |
| Everolimus (RAD001) 70 mg/Week vs Everolimus (RAD001) 10 mg/Day: serious adverse events | 34 of 99 | 22 of 100 | 199 | NCT00419159 | Trial comparisons |
| Best Supportive Care vs Durvalumab Plus Tremelimumab and Best Supportive Care: deaths from any cause | 54 of 61 | 100 of 118 | 179 | NCT02870920 | Trial comparisons |
| Best Supportive Care vs Durvalumab Plus Tremelimumab and Best Supportive Care: serious adverse events | 0 of 61 | 55 of 118 | 179 | NCT02870920 | Trial comparisons |
| Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: deaths from any cause | 54 of 67 | 45 of 68 | 135 | NCT01516216 | Trial comparisons |
| Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: serious adverse events | 39 of 67 | 47 of 68 | 135 | NCT01516216 | Trial comparisons |
| Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: Number of Participants With Vitamin D Deficiency at Baseline | 39 of 61 | 48 of 63 | 124 | NCT01516216 | Trial comparisons |
| Bevacizumab+Capecitabine+Oxaliplatin vs Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C: serious adverse events | 12 of 62 | 21 of 61 | 123 | NCT00623805 | Trial comparisons |
| Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: deaths from any cause | 1 of 25 | 0 of 26 | 51 | NCT00088413 | Trial comparisons |
Colorectal Cancer and Non-Colorectal Cancer Cohort vs Breast Cancer and Ovarian Cancer Cohort: Number of Participants With Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v3.0 and v4.0 | 25 of 25 | 26 of 26 | 51 | NCT00088413 | Trial comparisons |
| Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: serious adverse events | 25 of 25 | 26 of 26 | 51 | NCT00088413 | Trial comparisons |
Colorectal Cancer Cohort vs Non-Colorectal Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Colorectal Cancer and Non-colorectal Cancer Cohort Post Vaccination | 3 of 9 | 6 of 9 | 18 | NCT00088413 | Trial comparisons |
Breast Cancer Cohort vs Ovarian Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Breast Cancer and Ovarian Cancer Cohorts Post Vaccination | 1 of 3 | 1 of 2 | 5 | NCT00088413 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005008/comparisons